5% Off
Recormon2000 IU/0.
Roche Bangladesh Ltd.
৳1343.30
Add to cart
Generic medicine
Erythropoietin Beta: Brands, Price & Uses in Bangladesh
Erythropoietin Beta is a recombinant human erythropoietin (an erythropoiesis-stimulating agent, ESA) indicated for the treatment of anemia associated with specific clinical conditions.
About Erythropoietin Beta
Indications of Erythropoietin Beta
Erythropoietin Beta is a recombinant human erythropoietin (an erythropoiesis-stimulating agent, ESA) indicated for the treatment of anemia associated with specific clinical conditions. Indications below are organized by strength of evidence.
Established / Approved Indications
- Anemia associated with chronic kidney disease (CKD), including patients on dialysis (hemodialysis or peritoneal dialysis) and patients not yet on dialysis.
- Chemotherapy-induced anemia in patients with non-myeloid malignancies, where anemia is due to the effect of concomitant chemotherapy, to reduce the need for red blood cell transfusion.
- Prevention of anemia of prematurity in low-birth-weight premature infants, in markets where this indication is approved.
- Increasing yield of autologous blood from patients enrolled in a pre-operative autologous blood donation programme, to reduce exposure to allogeneic blood transfusion.
Important Limitations
- Erythropoietin Beta is not indicated for anemia due to iron, folate, or vitamin B12 deficiency, hemolysis, or bleeding; these underlying causes should be corrected first.
- Erythropoietin Beta is not intended to be used for the elective enhancement of athletic performance; such misuse can cause life-threatening cardiovascular complications.
- Use in cancer patients is intended only during a course of chemotherapy and only when anemia is not immediately life-threatening (see Precautions and Warnings for tumor progression risk).
Dosage & Administration of Erythropoietin Beta
Dosage of Erythropoietin Beta must be individualized for each patient based on the indication, baseline hemoglobin, rate of hemoglobin rise, and clinical response, using the lowest dose sufficient to reduce the need for red blood cell transfusion. Hemoglobin should not be increased above 12 g/dL, and treatment should not be used to normalize hemoglobin.
| Indication | Route | Typical Starting Dose | Titration |
|---|---|---|---|
| Anemia of CKD (adult) | Subcutaneous or intravenous | Approximately 3 × 20 IU/kg weekly (divided doses) | May increase by ~3 × 20 IU/kg every 4 weeks if hemoglobin rise is inadequate, up to a labeled maximum |
| Anemia of CKD (pediatric) | Subcutaneous or intravenous | Similar weight-based regimen as adults; younger children may need relatively higher doses | Individualized; specialist supervision required |
| Chemotherapy-induced anemia | Subcutaneous | Approximately 30,000 IU once weekly (or equivalent divided weekly dose) | May be adjusted if hemoglobin response is inadequate after 4 weeks, up to a labeled maximum; discontinue after chemotherapy course ends (approximately 4 weeks after) |
| Prevention of anemia of prematurity | Subcutaneous | Approximately 3 × 250 IU/kg weekly | Typically continued for about 6 weeks under neonatal specialist supervision |
| Autologous blood donation | Intravenous or subcutaneous | Individualized twice-weekly dosing for approximately 3–4 weeks before surgery | Subject to labeled maximum weekly dose; only under specialist supervision |
Doses and schedules above are general ranges; the prescribing physician's specific instructions and product labeling for the exact brand dispensed must always be followed. Renal and hepatic impairment do not have well-established formal dose adjustment tables for Erythropoietin Beta, since renal impairment (CKD) is itself a primary indication; dosing is instead guided by hemoglobin response and clinical monitoring in all populations, including those with hepatic impairment.
Side Effects of Erythropoietin Beta
Common and serious adverse effects reported with Erythropoietin Beta include:
- Very common/common: Hypertension, headache, injection-site reactions, flu-like symptoms (fever, chills, myalgia), arthralgia, and in premature infants, iron deficiency.
- Thromboembolic events: Including vascular access thrombosis in dialysis patients and venous thromboembolism in cancer patients (reported at a higher rate than in untreated controls).
- Rare but serious: Pure red cell aplasia (see Contraindications), severe cutaneous adverse reactions including Stevens-Johnson syndrome and toxic epidermal necrolysis, anaphylactoid/hypersensitivity reactions, and seizures.
For the class-level boxed-warning risks of increased mortality, cardiovascular events, and tumor progression associated with higher hemoglobin targets, see Precautions and Warnings.
Contraindications of Erythropoietin Beta
Erythropoietin Beta is contraindicated in patients with:
- Known hypersensitivity to Erythropoietin Beta (epoetin beta), any other erythropoietin product, or any excipient of the formulation.
- Uncontrolled hypertension.
- Pure red cell aplasia (PRCA) that began after treatment with any erythropoietin-based product, due to anti-erythropoietin neutralizing antibodies; patients with antibody-mediated PRCA must not be switched to and treated with Erythropoietin Beta or any other erythropoiesis-stimulating agent, because of cross-reactivity risk.
Additional situation-specific contraindications apply to the autologous blood donation setting (e.g., recent myocardial infarction or stroke, unstable angina, active venous thromboembolism); see product labeling for that specific use.
Frequently Asked Questions about Erythropoietin Beta
What is Erythropoietin Beta used for?
Erythropoietin Beta is used to treat anemia (low red blood cell count) caused by chronic kidney disease and by cancer chemotherapy, and in some settings to help boost blood levels before planned surgery or to prevent anemia in certain premature infants.
How is Erythropoietin Beta given?
Erythropoietin Beta is given only as an injection, either under the skin (subcutaneous) or into a vein (intravenous), never as a tablet or syrup. The dose and schedule are individualized by your physician based on your hemoglobin level and response.
Who should not use Erythropoietin Beta?
Erythropoietin Beta should not be used by people who are allergic to Erythropoietin Beta or similar erythropoietin products, those with uncontrolled high blood pressure, or those who previously developed pure red cell aplasia (a rare antibody-mediated condition) after treatment with any erythropoietin-type medicine.
Is Erythropoietin Beta safe during pregnancy or breastfeeding?
Data on use in pregnancy are limited, so Erythropoietin Beta should be used during pregnancy only if clearly needed and the potential benefit outweighs the potential risk to the baby, as advised by a physician. Whether it passes into breast milk in significant amounts is not well established, so a doctor should weigh the benefits of breastfeeding against the benefits of continuing therapy before deciding.
What are the serious risks of Erythropoietin Beta?
Erythropoietin Beta and similar medicines can increase the risk of death, heart attack, stroke, blood clots, and (in cancer patients) faster tumor growth or recurrence when the blood count is raised higher than necessary. Because of this, the lowest effective dose is used and blood pressure, hemoglobin, and iron levels are monitored regularly during treatment.
What should I do if I miss a dose or suspect an overdose of Erythropoietin Beta?
If you miss a scheduled dose, contact your physician or clinic for guidance rather than doubling the next dose. If an overdose is suspected, seek immediate medical attention or contact emergency services or a poison control center right away, since excessive doses can raise the blood count too high and increase the risk of dangerous blood pressure and clotting problems.
Disclaimer
The information provided is accurate to the best of our knowledge, but it does not replace professional medical advice. We cannot guarantee its completeness or accuracy, and the absence of specific information about a drug should not be taken as an endorsement. We are not responsible for any consequences arising from this information, so please consult a healthcare professional for any concerns or questions.